Genentech’s Perjeta Regimen Helped People with HER2-positive Early Breast Cancer Live Longer without Their Disease Returning or Getting Worse Compared to Herceptin and Chemotherapy
About BreastCancerBreastcancer is the most common cancer … with breastcancer. HER2-positive cancer is a particularly
aggressive form of breastcancer.
About Genentech in HER2-positive BreastCancer
Genentech has spent …